MYH9

Across TCGA pan-cancer cohorts, MYH9 Mutation is linked to patient survival in 12 of 34 cancer types, making it a survival-associated MYH9 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MYH9 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MYH9 expression acts as an unfavorable survival marker, although some lineages such as OV and BLCA show a favorable association.

OV, LIHC, and BLCA are the cancer types where MYH9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	1.000	0.372	.003	32	view →
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	12	view →
BLCA	DFS	Median	All	1.000	0.298	.015	12	view →
LUAD	OS	Median	All	0.017	0.788	<.001	12	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	9	view →
HNSC	DFS	Median	II,III,IV	0.118	0.667	<.001	9	view →
GBM	OS	Median	All	0.005	0.416	<.001	6	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	.006	6	view →
SKCM	OS	Median	III,IV	0.297	0.737	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
UCEC	DFS	Median	II,III,IV	0.846	0.433	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

MYH9–OV (DFS)

Open the OV breakdown →